Related Experiment Video
Updated: Aug 5, 2026
07:49
Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Navigating the Metabolic-Genomic Paradigm: Mitochondrial Reprogramming as a Driver of Cancer Plasticity
Yen-Dun Tony Tzeng1,2, Chen-Yueh Wen3,4, Su-Boon Yong5,6
1Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Oncology Research
|July 25, 2026
Summary
Integrating mitochondrial metabolism into breast cancer precision medicine offers new therapeutic strategies. Understanding metabolic reprogramming and targeting tumor vulnerabilities can improve patient outcomes and overcome treatment resistance.
Area of Science:
- Mitochondrial biology
- Cancer metabolism
- Precision oncology
Background:
- Breast cancer (BC) management evolves from histology to molecular subtyping.
- Therapeutic resistance and intratumor heterogeneity remain significant clinical challenges.
- Mitochondrial metabolism integration offers a new paradigm for BC precision medicine.
Purpose of the Study:
- To review the integration of mitochondrial metabolism in breast cancer precision medicine.
- To detail mitonuclear crosstalk in BC genetic alterations.
- To evaluate diagnostic and therapeutic strategies targeting mitochondrial vulnerabilities.
Main Methods:
- Review of scientific literature and clinical trial data.
- Analysis of molecular mechanisms of mitochondrial reprogramming in BC.
- Evaluation of diagnostic biomarkers (mtDNA heteroplasmy, metabolic gene signatures) and therapeutic targets (metabolic inhibitors).
Main Results:
- Nuclear genetic alterations (e.g., BRCA1 deficiency, TP53 mutations) reprogram mitochondrial bioenergetics.
- Mitochondrial DNA heteroplasmy and metabolic gene signatures show potential as biomarkers.
- Targeting mitochondrial vulnerabilities faces challenges from metabolic plasticity; patient selection is crucial.
Conclusions:
- Integrating mitochondrial metabolism with genomic data is key for BC precision oncology.
- AI and metabolic modeling can identify novel synthetic lethal targets.
- Future strategies require precise patient stratification based on metabolic phenotypes for effective interventions.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...